CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 140 enrolled
Drug / intervention
cycloplegic refractionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04537065
NCT04537065N/ACompleted
CompareCT.gov

Refractive and Biometric Outcome Following Intravitreal Injection of Ranibizumab in Retinopathy of Prematurity: Long -Term Study

Ameera Gamal Abdelhameed·observational·Posted Sep 3, 2020·Updated Sep 3, 2020

In Brief

An observational study evaluating cycloplegic refraction for Retinopathy of Prematurity. Completed, enrolled 140 participants across 1 site.

Detailed Summary

premature infants who had a history of intravitreal injection of (Ranibizumab) not less than one year were examined for refractive state and biometry

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRetinopathy of Prematurity
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 3, 2020
Enrollment StartApr 1, 2018
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.8 years ago

Interventions

cycloplegic refractionother

Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder. The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).